| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wound Healing | 25 | 2023 | 454 | 6.050 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 23 | 2024 | 381 | 4.150 |
Why?
|
| Interleukin-10 | 12 | 2023 | 170 | 4.140 |
Why?
|
| Biomedical Research | 13 | 2023 | 510 | 3.890 |
Why?
|
| Surgeons | 9 | 2023 | 244 | 3.030 |
Why?
|
| Hyaluronic Acid | 11 | 2021 | 95 | 2.820 |
Why?
|
| Cicatrix | 6 | 2023 | 125 | 2.670 |
Why?
|
| Lung | 19 | 2024 | 1476 | 2.050 |
Why?
|
| Fetus | 10 | 2023 | 579 | 1.980 |
Why?
|
| Skin | 8 | 2023 | 503 | 1.890 |
Why?
|
| Respiratory System Abnormalities | 8 | 2024 | 42 | 1.840 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2024 | 86 | 1.830 |
Why?
|
| Gene Transfer Techniques | 10 | 2015 | 374 | 1.740 |
Why?
|
| Fibroblasts | 5 | 2020 | 878 | 1.670 |
Why?
|
| Neovascularization, Physiologic | 8 | 2022 | 209 | 1.630 |
Why?
|
| Awards and Prizes | 3 | 2023 | 63 | 1.620 |
Why?
|
| Writing | 3 | 2021 | 57 | 1.580 |
Why?
|
| Career Mobility | 3 | 2021 | 51 | 1.570 |
Why?
|
| Fetoscopy | 12 | 2024 | 425 | 1.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 8 | 2024 | 624 | 1.500 |
Why?
|
| Wounds and Injuries | 6 | 2020 | 349 | 1.490 |
Why?
|
| Ultrasonography, Prenatal | 17 | 2024 | 901 | 1.460 |
Why?
|
| Extracellular Matrix | 8 | 2020 | 230 | 1.450 |
Why?
|
| Intestines | 3 | 2021 | 576 | 1.410 |
Why?
|
| Prenatal Diagnosis | 12 | 2024 | 580 | 1.340 |
Why?
|
| Trachea | 9 | 2024 | 197 | 1.300 |
Why?
|
| Fetal Development | 3 | 2015 | 110 | 1.230 |
Why?
|
| Mentors | 3 | 2021 | 145 | 1.190 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 257 | 1.190 |
Why?
|
| Research Support as Topic | 2 | 2021 | 61 | 1.160 |
Why?
|
| Discrete Subaortic Stenosis | 2 | 2024 | 7 | 1.150 |
Why?
|
| Phenyl Ethers | 2 | 2024 | 9 | 1.150 |
Why?
|
| Pregnancy | 46 | 2024 | 7092 | 1.150 |
Why?
|
| Infant, Newborn | 42 | 2024 | 8096 | 1.150 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2023 | 127 | 1.130 |
Why?
|
| Financing, Organized | 3 | 2022 | 19 | 1.110 |
Why?
|
| Genetic Therapy | 4 | 2015 | 706 | 1.090 |
Why?
|
| Hypertension, Pulmonary | 4 | 2024 | 428 | 1.040 |
Why?
|
| Gestational Age | 10 | 2024 | 1115 | 1.030 |
Why?
|
| Humans | 107 | 2024 | 122296 | 0.970 |
Why?
|
| Bioprinting | 1 | 2024 | 9 | 0.970 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 59 | 0.950 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2021 | 25 | 0.940 |
Why?
|
| Gastroschisis | 2 | 2021 | 53 | 0.930 |
Why?
|
| General Surgery | 3 | 2019 | 203 | 0.920 |
Why?
|
| Wound Infection | 4 | 2022 | 51 | 0.920 |
Why?
|
| Pediatrics | 4 | 2019 | 1140 | 0.910 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 217 | 0.900 |
Why?
|
| Hydrops Fetalis | 3 | 2020 | 75 | 0.890 |
Why?
|
| Fetal Therapies | 3 | 2018 | 72 | 0.890 |
Why?
|
| Teratoma | 7 | 2024 | 125 | 0.890 |
Why?
|
| Kidney | 3 | 2021 | 1340 | 0.880 |
Why?
|
| Lung Diseases | 6 | 2023 | 384 | 0.870 |
Why?
|
| Dependovirus | 3 | 2013 | 125 | 0.870 |
Why?
|
| Genetic Vectors | 5 | 2013 | 969 | 0.840 |
Why?
|
| Bandages | 2 | 2020 | 56 | 0.840 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2015 | 340 | 0.820 |
Why?
|
| Cystic Fibrosis | 3 | 2012 | 261 | 0.820 |
Why?
|
| Obstetric Labor, Premature | 1 | 2023 | 85 | 0.820 |
Why?
|
| Cell Survival | 1 | 2024 | 816 | 0.810 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 257 | 0.800 |
Why?
|
| Retrospective Studies | 48 | 2024 | 15853 | 0.790 |
Why?
|
| Pulmonary Fibrosis | 2 | 2020 | 96 | 0.790 |
Why?
|
| Actins | 1 | 2024 | 339 | 0.790 |
Why?
|
| Animals | 39 | 2024 | 33721 | 0.780 |
Why?
|
| Female | 70 | 2024 | 64883 | 0.780 |
Why?
|
| Dermis | 1 | 2021 | 24 | 0.780 |
Why?
|
| Molecular Weight | 3 | 2021 | 390 | 0.770 |
Why?
|
| Budgets | 1 | 2021 | 18 | 0.760 |
Why?
|
| Abdominal Wall | 1 | 2021 | 32 | 0.760 |
Why?
|
| Mice | 31 | 2024 | 17546 | 0.750 |
Why?
|
| Adenoviridae | 6 | 2015 | 637 | 0.730 |
Why?
|
| Perinatal Care | 2 | 2022 | 68 | 0.720 |
Why?
|
| Mice, Inbred C57BL | 19 | 2023 | 4366 | 0.720 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2022 | 11 | 0.710 |
Why?
|
| Skin Care | 1 | 2020 | 14 | 0.710 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2020 | 51 | 0.710 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 30 | 0.700 |
Why?
|
| Time-to-Treatment | 2 | 2018 | 187 | 0.700 |
Why?
|
| Gastrostomy | 2 | 2020 | 84 | 0.690 |
Why?
|
| Disease Models, Animal | 9 | 2024 | 4282 | 0.690 |
Why?
|
| Debridement | 1 | 2020 | 84 | 0.690 |
Why?
|
| Emergency Treatment | 1 | 2020 | 86 | 0.670 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 469 | 0.660 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2022 | 413 | 0.660 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 298 | 0.660 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 193 | 0.650 |
Why?
|
| Science | 1 | 2019 | 32 | 0.650 |
Why?
|
| Heart Defects, Congenital | 4 | 2024 | 1799 | 0.630 |
Why?
|
| Academies and Institutes | 1 | 2019 | 81 | 0.630 |
Why?
|
| Fetal Diseases | 8 | 2024 | 443 | 0.630 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 187 | 0.620 |
Why?
|
| Herniorrhaphy | 1 | 2018 | 80 | 0.600 |
Why?
|
| Heart Transplantation | 1 | 2024 | 853 | 0.580 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2019 | 469 | 0.560 |
Why?
|
| Sacrococcygeal Region | 4 | 2024 | 32 | 0.560 |
Why?
|
| Cells, Cultured | 7 | 2024 | 3074 | 0.530 |
Why?
|
| Length of Stay | 8 | 2024 | 1273 | 0.530 |
Why?
|
| Pandemics | 2 | 2021 | 1102 | 0.530 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2015 | 139 | 0.520 |
Why?
|
| Angiopoietin-1 | 1 | 2015 | 7 | 0.510 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2015 | 21 | 0.510 |
Why?
|
| Pseudomonas Infections | 3 | 2022 | 113 | 0.490 |
Why?
|
| Placental Insufficiency | 1 | 2015 | 13 | 0.490 |
Why?
|
| Efficiency | 1 | 2015 | 57 | 0.480 |
Why?
|
| Myocardium | 1 | 2020 | 980 | 0.480 |
Why?
|
| Placenta | 3 | 2023 | 487 | 0.470 |
Why?
|
| Algorithms | 2 | 2022 | 1575 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1244 | 0.460 |
Why?
|
| Postoperative Complications | 4 | 2020 | 2997 | 0.460 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 139 | 0.450 |
Why?
|
| Skin Physiological Phenomena | 2 | 2013 | 19 | 0.450 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1678 | 0.450 |
Why?
|
| Palate | 1 | 2013 | 11 | 0.440 |
Why?
|
| Gallbladder | 1 | 2013 | 19 | 0.440 |
Why?
|
| Cholecystitis | 1 | 2013 | 20 | 0.440 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2013 | 5 | 0.440 |
Why?
|
| Mouth Mucosa | 1 | 2013 | 51 | 0.430 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 3 | 2022 | 20 | 0.430 |
Why?
|
| Infant | 19 | 2024 | 12302 | 0.430 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 216 | 0.430 |
Why?
|
| United States | 9 | 2023 | 10487 | 0.420 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2011 | 45 | 0.420 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 96 | 0.420 |
Why?
|
| Saliva | 1 | 2013 | 113 | 0.410 |
Why?
|
| Pressure Ulcer | 1 | 2013 | 76 | 0.410 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 269 | 0.410 |
Why?
|
| Inflammation | 5 | 2024 | 1392 | 0.410 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 36 | 0.410 |
Why?
|
| Viral Tropism | 1 | 2012 | 34 | 0.400 |
Why?
|
| Cytokines | 4 | 2024 | 1272 | 0.400 |
Why?
|
| Male | 32 | 2024 | 59522 | 0.400 |
Why?
|
| Viral Proteins | 1 | 2014 | 348 | 0.400 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 169 | 0.380 |
Why?
|
| Research Personnel | 4 | 2022 | 117 | 0.380 |
Why?
|
| Exocrine Glands | 1 | 2011 | 8 | 0.370 |
Why?
|
| Child Development | 1 | 2013 | 249 | 0.360 |
Why?
|
| Pneumonectomy | 2 | 2018 | 140 | 0.360 |
Why?
|
| Airway Obstruction | 2 | 2023 | 165 | 0.360 |
Why?
|
| Macrophages | 3 | 2024 | 611 | 0.350 |
Why?
|
| Keratinocytes | 3 | 2016 | 60 | 0.350 |
Why?
|
| Endothelial Cells | 2 | 2024 | 527 | 0.350 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 3448 | 0.350 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 237 | 0.340 |
Why?
|
| Hymecromone | 2 | 2021 | 5 | 0.340 |
Why?
|
| Treatment Outcome | 16 | 2024 | 12045 | 0.340 |
Why?
|
| Echocardiography | 3 | 2019 | 1066 | 0.310 |
Why?
|
| Vagina | 2 | 2020 | 201 | 0.310 |
Why?
|
| Signal Transduction | 2 | 2020 | 4511 | 0.300 |
Why?
|
| Pelvic Neoplasms | 2 | 2022 | 21 | 0.300 |
Why?
|
| Spinal Neoplasms | 2 | 2022 | 59 | 0.300 |
Why?
|
| Clinical Competence | 1 | 2015 | 972 | 0.300 |
Why?
|
| Quality Improvement | 1 | 2013 | 620 | 0.290 |
Why?
|
| Immune Tolerance | 2 | 2019 | 145 | 0.280 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2024 | 26 | 0.280 |
Why?
|
| Stress, Mechanical | 2 | 2024 | 171 | 0.280 |
Why?
|
| Cell Movement | 3 | 2015 | 838 | 0.270 |
Why?
|
| Organ Culture Techniques | 3 | 2014 | 155 | 0.270 |
Why?
|
| Prenatal Care | 4 | 2023 | 340 | 0.270 |
Why?
|
| Mice, SCID | 2 | 2021 | 570 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 812 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 282 | 0.250 |
Why?
|
| Hospitals, Pediatric | 3 | 2024 | 776 | 0.240 |
Why?
|
| Alginates | 1 | 2024 | 18 | 0.240 |
Why?
|
| Poloxamer | 1 | 2024 | 12 | 0.240 |
Why?
|
| Porosity | 1 | 2024 | 39 | 0.240 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 19 | 0.240 |
Why?
|
| Internship and Residency | 1 | 2015 | 1153 | 0.240 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 130 | 0.240 |
Why?
|
| Bronchi | 1 | 2005 | 100 | 0.230 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 2080 | 0.230 |
Why?
|
| Organ Size | 5 | 2019 | 411 | 0.230 |
Why?
|
| Child | 14 | 2022 | 24064 | 0.230 |
Why?
|
| Lymphatic Abnormalities | 1 | 2024 | 35 | 0.230 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2022 | 163 | 0.230 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 174 | 0.230 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 66 | 0.230 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 58 | 0.220 |
Why?
|
| Adolescent | 10 | 2022 | 18940 | 0.220 |
Why?
|
| Survival Rate | 6 | 2019 | 1997 | 0.220 |
Why?
|
| Amniotic Band Syndrome | 1 | 2003 | 24 | 0.210 |
Why?
|
| Academic Success | 1 | 2023 | 20 | 0.210 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2024 | 144 | 0.210 |
Why?
|
| Biofilms | 2 | 2022 | 93 | 0.210 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 217 | 0.210 |
Why?
|
| Inovirus | 1 | 2022 | 2 | 0.210 |
Why?
|
| Hysterotomy | 2 | 2021 | 118 | 0.210 |
Why?
|
| Balloon Occlusion | 1 | 2022 | 43 | 0.210 |
Why?
|
| Limb Salvage | 1 | 2003 | 117 | 0.210 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2024 | 311 | 0.200 |
Why?
|
| Hydronephrosis | 2 | 2013 | 35 | 0.200 |
Why?
|
| Cohort Studies | 7 | 2021 | 4643 | 0.200 |
Why?
|
| Infant, Premature, Diseases | 1 | 2024 | 239 | 0.200 |
Why?
|
| Mice, Knockout | 3 | 2015 | 3770 | 0.200 |
Why?
|
| Transduction, Genetic | 2 | 2013 | 297 | 0.190 |
Why?
|
| Polyhydramnios | 1 | 2021 | 51 | 0.190 |
Why?
|
| Neck | 2 | 2024 | 134 | 0.190 |
Why?
|
| Fibrosis | 2 | 2021 | 428 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 458 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3626 | 0.190 |
Why?
|
| Infant Mortality | 2 | 2020 | 175 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 5 | 1 | 2021 | 4 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2022 | 3307 | 0.190 |
Why?
|
| Cerebrospinal Fluid Leak | 2 | 2020 | 43 | 0.190 |
Why?
|
| Hemodynamics | 2 | 2022 | 839 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 212 | 0.180 |
Why?
|
| Prognosis | 6 | 2024 | 4488 | 0.180 |
Why?
|
| Graft Rejection | 1 | 2024 | 576 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2022 | 13777 | 0.180 |
Why?
|
| Patient Selection | 2 | 2021 | 685 | 0.180 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 181 | 0.180 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 47 | 0.180 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 23 | 0.180 |
Why?
|
| Ointments | 1 | 2020 | 14 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 546 | 0.180 |
Why?
|
| Surgical Wound | 1 | 2020 | 24 | 0.180 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 296 | 0.180 |
Why?
|
| Animals, Newborn | 1 | 2024 | 1007 | 0.180 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2020 | 16 | 0.180 |
Why?
|
| Simulation Training | 1 | 2022 | 139 | 0.180 |
Why?
|
| Muscle Proteins | 1 | 2023 | 415 | 0.180 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 237 | 0.180 |
Why?
|
| Organ Specificity | 1 | 2021 | 427 | 0.170 |
Why?
|
| Multigene Family | 1 | 2021 | 299 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 1710 | 0.170 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 110 | 0.170 |
Why?
|
| Edema | 4 | 2023 | 133 | 0.170 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 245 | 0.170 |
Why?
|
| Abdomen | 1 | 2020 | 128 | 0.160 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2021 | 138 | 0.160 |
Why?
|
| Pseudomonas Phages | 1 | 2019 | 10 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2030 | 0.160 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 265 | 0.160 |
Why?
|
| Adult | 14 | 2024 | 28733 | 0.160 |
Why?
|
| Uterus | 1 | 2003 | 590 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2024 | 799 | 0.160 |
Why?
|
| Bleomycin | 1 | 2019 | 150 | 0.160 |
Why?
|
| Hydrogels | 1 | 2019 | 77 | 0.160 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 845 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2019 | 170 | 0.150 |
Why?
|
| Meningomyelocele | 1 | 2021 | 222 | 0.150 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2011 | 16 | 0.150 |
Why?
|
| Regeneration | 1 | 2020 | 202 | 0.150 |
Why?
|
| Gynecology | 1 | 2019 | 126 | 0.150 |
Why?
|
| Estrogens | 1 | 2020 | 506 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 131 | 0.150 |
Why?
|
| Oropharynx | 1 | 2017 | 33 | 0.150 |
Why?
|
| Liver | 4 | 2022 | 1851 | 0.150 |
Why?
|
| Career Choice | 1 | 2019 | 143 | 0.150 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 636 | 0.150 |
Why?
|
| Time Factors | 3 | 2024 | 6182 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2020 | 262 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 160 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2022 | 767 | 0.140 |
Why?
|
| Financing, Government | 1 | 2017 | 30 | 0.140 |
Why?
|
| Transcriptome | 1 | 2023 | 904 | 0.140 |
Why?
|
| Insufflation | 1 | 2017 | 20 | 0.140 |
Why?
|
| Glycosaminoglycans | 2 | 2021 | 35 | 0.140 |
Why?
|
| Disease Management | 1 | 2021 | 511 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 182 | 0.140 |
Why?
|
| Flow Cytometry | 3 | 2015 | 810 | 0.140 |
Why?
|
| Neural Tube Defects | 1 | 2020 | 351 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2311 | 0.140 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2016 | 32 | 0.140 |
Why?
|
| Telemedicine | 1 | 2022 | 422 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2013 | 941 | 0.130 |
Why?
|
| Anxiety | 1 | 2023 | 950 | 0.130 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 274 | 0.130 |
Why?
|
| Forecasting | 1 | 2017 | 355 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 335 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5013 | 0.130 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 97 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2817 | 0.130 |
Why?
|
| Survivors | 1 | 2018 | 345 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 635 | 0.120 |
Why?
|
| Biomarkers | 2 | 2015 | 2933 | 0.120 |
Why?
|
| Thoracic Cavity | 1 | 2014 | 2 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 93 | 0.120 |
Why?
|
| Lung Volume Measurements | 3 | 2023 | 67 | 0.120 |
Why?
|
| Allergens | 1 | 2017 | 244 | 0.120 |
Why?
|
| Cell Nucleus | 2 | 2017 | 678 | 0.120 |
Why?
|
| Depression | 1 | 2023 | 1214 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2020 | 502 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 507 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 716 | 0.110 |
Why?
|
| Octreotide | 1 | 2013 | 21 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 62 | 0.110 |
Why?
|
| Chylothorax | 1 | 2013 | 26 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 968 | 0.110 |
Why?
|
| Submandibular Gland | 1 | 2013 | 7 | 0.110 |
Why?
|
| Probability | 2 | 2024 | 319 | 0.110 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2013 | 5 | 0.110 |
Why?
|
| Critical Illness | 1 | 2018 | 588 | 0.110 |
Why?
|
| Spinal Dysraphism | 1 | 2017 | 262 | 0.110 |
Why?
|
| Ovarian Diseases | 1 | 2013 | 27 | 0.110 |
Why?
|
| Torsion Abnormality | 1 | 2013 | 34 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 2013 | 99 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2013 | 79 | 0.100 |
Why?
|
| Fetal Stem Cells | 1 | 2012 | 5 | 0.100 |
Why?
|
| Young Adult | 6 | 2021 | 8760 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 768 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 231 | 0.100 |
Why?
|
| Quality of Life | 2 | 2022 | 1913 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2534 | 0.100 |
Why?
|
| Growth Substances | 1 | 2012 | 113 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 217 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 391 | 0.100 |
Why?
|
| Mice, Inbred CFTR | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cecal Diseases | 1 | 2010 | 6 | 0.090 |
Why?
|
| Appendix | 1 | 2010 | 15 | 0.090 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 45 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 234 | 0.090 |
Why?
|
| Hemangioblasts | 1 | 2010 | 2 | 0.090 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2010 | 15 | 0.090 |
Why?
|
| Immunity | 2 | 2022 | 182 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 33 | 0.090 |
Why?
|
| Postnatal Care | 3 | 2019 | 51 | 0.090 |
Why?
|
| Fetal Death | 2 | 2013 | 115 | 0.090 |
Why?
|
| Ohio | 3 | 2014 | 88 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2013 | 391 | 0.090 |
Why?
|
| Heart | 1 | 2015 | 723 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2010 | 1004 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 137 | 0.080 |
Why?
|
| Hyaluronan Receptors | 2 | 2021 | 66 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 1613 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 962 | 0.080 |
Why?
|
| Urogenital Abnormalities | 1 | 2011 | 163 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 923 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 468 | 0.080 |
Why?
|
| Hernia, Umbilical | 1 | 2008 | 42 | 0.080 |
Why?
|
| Apoptosis | 1 | 2015 | 1790 | 0.080 |
Why?
|
| Drainage | 1 | 2010 | 254 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 3528 | 0.080 |
Why?
|
| Neoplasms | 1 | 2022 | 2753 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 979 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2013 | 1158 | 0.080 |
Why?
|
| Hernia, Diaphragmatic | 3 | 2013 | 97 | 0.070 |
Why?
|
| Salivary Glands | 1 | 2007 | 32 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2010 | 281 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 109 | 0.070 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 158 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 276 | 0.070 |
Why?
|
| Ileum | 1 | 2007 | 134 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2021 | 404 | 0.070 |
Why?
|
| Physicians | 1 | 2013 | 582 | 0.070 |
Why?
|
| Pregnancy Outcome | 3 | 2017 | 592 | 0.070 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2005 | 7 | 0.060 |
Why?
|
| Anesthesia, Epidural | 1 | 2005 | 14 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2005 | 12 | 0.060 |
Why?
|
| Fentanyl | 1 | 2005 | 43 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2017 | 117 | 0.060 |
Why?
|
| Streptozocin | 1 | 2004 | 25 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 3018 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2024 | 40 | 0.060 |
Why?
|
| Airway Management | 1 | 2024 | 66 | 0.060 |
Why?
|
| Surface-Active Agents | 1 | 2024 | 31 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 356 | 0.060 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 285 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 231 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3301 | 0.060 |
Why?
|
| Lentivirus | 1 | 2004 | 84 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 388 | 0.060 |
Why?
|
| Wrist | 1 | 2003 | 24 | 0.050 |
Why?
|
| Models, Animal | 2 | 2020 | 465 | 0.050 |
Why?
|
| Sirolimus | 1 | 2024 | 220 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 315 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2022 | 50 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 182 | 0.050 |
Why?
|
| Universities | 1 | 2023 | 126 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2022 | 79 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 768 | 0.050 |
Why?
|
| Propylene Glycol | 1 | 2021 | 8 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 180 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2021 | 25 | 0.050 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 5 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 60 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2010 | 0.050 |
Why?
|
| Disaccharides | 1 | 2021 | 13 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 68 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 93 | 0.050 |
Why?
|
| Patient Preference | 1 | 2022 | 100 | 0.050 |
Why?
|
| Thorax | 1 | 2021 | 73 | 0.050 |
Why?
|
| Intubation, Intratracheal | 1 | 2024 | 289 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 237 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 261 | 0.050 |
Why?
|
| Mast Cells | 1 | 2021 | 75 | 0.050 |
Why?
|
| Immune System | 1 | 2021 | 86 | 0.050 |
Why?
|
| Diaphragm | 1 | 2021 | 97 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 89 | 0.050 |
Why?
|
| Water | 1 | 2021 | 181 | 0.050 |
Why?
|
| Counseling | 1 | 2022 | 218 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 5963 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 351 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 79 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 162 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 386 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 410 | 0.040 |
Why?
|
| Heparin | 1 | 2021 | 229 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 269 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 346 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2019 | 33 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2022 | 438 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 581 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 996 | 0.040 |
Why?
|
| Middle Aged | 2 | 2021 | 25640 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 240 | 0.040 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2019 | 18 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 222 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2019 | 44 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 548 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1283 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 38 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 525 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 374 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 517 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 119 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2013 | 1468 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1315 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 461 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 457 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 236 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 666 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 2777 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1413 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2021 | 426 | 0.040 |
Why?
|
| Endoscopy | 1 | 2019 | 282 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2019 | 206 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 645 | 0.040 |
Why?
|
| Perinatal Mortality | 1 | 2017 | 42 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 342 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 66 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 444 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 53 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 582 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2017 | 55 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 159 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 128 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 671 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 369 | 0.030 |
Why?
|
| Stents | 1 | 2022 | 864 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 302 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 261 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1935 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2796 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 1204 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 461 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 668 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 841 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 111 | 0.030 |
Why?
|
| Chest Tubes | 1 | 2013 | 36 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2013 | 27 | 0.030 |
Why?
|
| Cardiac Output, High | 1 | 2013 | 2 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 2385 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 325 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 552 | 0.030 |
Why?
|
| Nausea | 1 | 2013 | 98 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 9902 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 104 | 0.030 |
Why?
|
| Vomiting | 1 | 2013 | 116 | 0.030 |
Why?
|
| Tidal Volume | 1 | 2011 | 36 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2441 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 804 | 0.020 |
Why?
|
| Urinary Tract | 1 | 2011 | 59 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 17 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 13 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 308 | 0.020 |
Why?
|
| Hospital Records | 1 | 2010 | 8 | 0.020 |
Why?
|
| Ovary | 1 | 2013 | 390 | 0.020 |
Why?
|
| Soft Tissue Injuries | 1 | 2010 | 11 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 58 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1247 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 317 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 70 | 0.020 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 45 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 421 | 0.020 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 82 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 282 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 176 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1991 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 702 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 73 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1296 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2007 | 235 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 268 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 122 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 247 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1090 | 0.020 |
Why?
|
| Transgenes | 1 | 2007 | 330 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1490 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 1109 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 453 | 0.020 |
Why?
|
| Bupivacaine | 1 | 2005 | 21 | 0.020 |
Why?
|
| Aged | 1 | 2003 | 18785 | 0.020 |
Why?
|
| Tobramycin | 1 | 2005 | 23 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2005 | 143 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 66 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1703 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 79 | 0.010 |
Why?
|
| Thoracotomy | 1 | 2005 | 111 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2005 | 215 | 0.010 |
Why?
|
| Analgesics | 1 | 2005 | 131 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 266 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2826 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2005 | 274 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 450 | 0.010 |
Why?
|